ArticleBrain communications2025
Serum neuronal, glial and mitochondrial markers in autosomal dominant optic atrophy and Leber hereditary optic neuropathy.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leber hereditary optic neuropathy (LHON) and autosomal-dominant optic atrophy (ADOA) are the two most prevailing primary mitochondrial optic neuropathies. Both diseases preferentially affect the smallest retinal ganglion cells (GCs) of the papillomacular bundle, causing central visual loss in young patients. Although ADOA and LHON show striking similarities, including the convergence of underlying pathologic mitochondrial mechanisms, they differ clinically. The major distinction lies in the timing and progression of axonal damage during neurodegeneration. The exact reasons for these differences remain unclear, but they may, in part, be due to distinct patterns of mitochondrial dysfunction. To identify differences that could point to distinct degenerative processes, we investigated clinical features, optical coherence tomography (OCT) findings, laboratory biomarkers [serum neurofilaments light chain (sNfL), serum glial fibrillary acidic protein (sGFAP) and serum growth differentiation factor-15 (sGDF15)] in a cohort of patients with these two heritable optic neuropathies in the chronic phase. Our OCT analysis reveals a more profound GC layer and papillomacular bundle loss in LHON, whereas ADOA shows a sparser damage of the retinal nerve fibre layer, including fibres originating from the nasal retina. We also observed increased plasma levels of sNfL and GFAP in both groups, supporting the presence of ongoing neurodegeneration in both optic neuropathies. Finally, our findings suggest the retinal astrocytes may play a contributive role in the neurodegenerative process at the level of the optic nerve head, particularly in ADOA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.